Actively Recruiting
Phase 1 Study of Peposertib and Low-Dose Liposomal Doxorubicin in Metastatic and Unresectable Soft Tissue Sarcomas
Led by National Cancer Institute (NCI) · Updated on 2026-11-04
30
Participants Needed
16
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, side effects, and best dose of a combination therapy using liposomal doxorubicin and peposertib in patients with advanced sarcoma. This includes sarcomas that have spread to other parts of the body metastatic or cannot be removed by surgery unresectable, and for which no known cure exists. The study is a phase 1 trial focusing on patients with specific types of soft tissue sarcomas, including leiomyosarcoma, and aims to find the maximum tolerated dose and recommended dose for future studies. Participants receive peposertib orally twice daily on days 1 through 28 of each 28-day cycle, along with liposomal doxorubicin administered intravenously on day 1 of each cycle. Treatment cycles continue unless the disease progresses, unacceptable side effects occur, or the participant chooses to withdraw. Throughout the study, patients undergo blood collections, computed tomography CT or magnetic resonance imaging MRI scans, tissue biopsies, and heart function tests echocardiography or multigated acquisition scan during screening and treatment. During the trial, researchers monitor participants closely for dose-limiting toxicities and adverse events, as well as treatment response and disease progression. Blood and tissue samples help assess drug effects and cancer activity, including biomarkers. Participants are followed for 30 days after stopping treatment or until death. The study involves regular visits for treatment administration and assessments, aiming to understand the combination therapys safety and optimal dosing in this patient group.
CONDITIONS
Brief Title
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here